CN108472311B - 抗病毒剂和治疗病毒感染的方法 - Google Patents

抗病毒剂和治疗病毒感染的方法 Download PDF

Info

Publication number
CN108472311B
CN108472311B CN201780005078.4A CN201780005078A CN108472311B CN 108472311 B CN108472311 B CN 108472311B CN 201780005078 A CN201780005078 A CN 201780005078A CN 108472311 B CN108472311 B CN 108472311B
Authority
CN
China
Prior art keywords
copolymer
molecular weight
acrolein
daltons
polyalkylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780005078.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN108472311A (zh
Inventor
G.J.H.梅尔罗斯
M.K.迪利齐亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recce Pharmaceuticals Ltd
Original Assignee
Recce Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900595A external-priority patent/AU2016900595A0/en
Application filed by Recce Pharmaceuticals Ltd filed Critical Recce Pharmaceuticals Ltd
Publication of CN108472311A publication Critical patent/CN108472311A/zh
Application granted granted Critical
Publication of CN108472311B publication Critical patent/CN108472311B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780005078.4A 2016-02-19 2017-02-17 抗病毒剂和治疗病毒感染的方法 Active CN108472311B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2016900595 2016-02-19
AU2016900595A AU2016900595A0 (en) 2016-02-19 Method for treatment of cancer or viral infection
AU2016902715A AU2016902715A0 (en) 2016-07-11 Method for treatment of cancer or viral infection
AU2016902715 2016-07-11
PCT/AU2017/050139 WO2017139849A1 (en) 2016-02-19 2017-02-17 Anti-virus agent and method for treatment of viral infection

Publications (2)

Publication Number Publication Date
CN108472311A CN108472311A (zh) 2018-08-31
CN108472311B true CN108472311B (zh) 2021-06-22

Family

ID=59624666

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780005078.4A Active CN108472311B (zh) 2016-02-19 2017-02-17 抗病毒剂和治疗病毒感染的方法

Country Status (7)

Country Link
US (2) US11045491B2 (enExample)
EP (1) EP3416656B1 (enExample)
JP (1) JP6812436B2 (enExample)
CN (1) CN108472311B (enExample)
AU (2) AU2017220391B2 (enExample)
ES (1) ES2867453T3 (enExample)
WO (1) WO2017139849A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL295116B2 (en) * 2020-01-31 2024-05-01 Recce Pharmaceuticals Ltd A process for preparing a biologically active copolymer that includes an acrolein derivative and a polyalkylene oligomer
US20210330700A1 (en) * 2020-04-23 2021-10-28 Johnson & Johnson Consumer Inc. Methods and compositions for inhibiting influenza viruses using low molecular weight hydrophobically modified polymers and polyalkylene glycols
WO2025129262A1 (en) * 2023-12-21 2025-06-26 Gramele Industrial Holdings Pty Ltd Methods of ameliorating microbial growth

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN87108390A (zh) * 1986-12-23 1988-09-21 生物聚合物有限公司 抑制生物和杀生物的组合物
AU2010100972A4 (en) * 2009-10-19 2010-10-07 Chemeq Ltd Topical antimicrobial compositions
CN103936895A (zh) * 2007-11-07 2014-07-23 瑞克私人有限公司 抗微生物聚合物及其组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2112381B (en) * 1981-09-30 1986-08-28 Nat Res Dev Cyclic ether and thioether derivatives for use as diluents in sustained release compositions
PH23983A (en) 1986-12-23 1990-02-09 Biopolymers Ltd Biostatic and biocidal composition
AUPN327695A0 (en) 1995-05-30 1995-06-22 Chemeq Pty. Limited Chemotherapeutic compositions
EP0792895B1 (de) 1996-02-22 2001-05-16 Degussa AG Acrolein freisetzende Copolymere
US6060571A (en) 1996-02-22 2000-05-09 Degussa Aktiengesellschaft Acrolein-releasing copolymers
US6060235A (en) * 1997-09-19 2000-05-09 Geltex Pharmaceuticals, Inc. Antiviral polymers comprising acid functional groups and hydrophobic groups
WO2001060874A1 (en) * 2000-02-16 2001-08-23 Chemeq Ltd. Antimicrobial polymeric compositions
US7629002B2 (en) 2000-02-16 2009-12-08 Chemeq Ltd. Antimicrobial polymeric compositions and method of treatment using them
AUPS327102A0 (en) * 2002-06-28 2002-07-18 Chemeq Ltd Method of treatment or prophylaxis of gastrointestinal diseases
CA2472685C (en) * 2002-01-18 2010-07-20 Chemeq Ltd Method of treatment of gastrointestinal disease and polymeric composition for use therein
ATE461226T1 (de) * 2003-11-06 2010-04-15 Chemeq Ltd Verfahren zur herstellung von polyacrolein
EP2186521A1 (en) * 2008-11-14 2010-05-19 Mergemeier Steffen Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
WO2011047420A1 (en) * 2009-10-19 2011-04-28 Chemeq Ltd Cosmetic compositions
WO2015160940A1 (en) * 2014-04-15 2015-10-22 President And Fellows Of Harvard College Bi-specific agents
JP6605602B2 (ja) * 2014-11-18 2019-11-13 レッセ ファーマシューティカルズ リミテッド 細菌感染の治療のためのコポリマーおよび方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN87108390A (zh) * 1986-12-23 1988-09-21 生物聚合物有限公司 抑制生物和杀生物的组合物
CN103936895A (zh) * 2007-11-07 2014-07-23 瑞克私人有限公司 抗微生物聚合物及其组合物
AU2010100972A4 (en) * 2009-10-19 2010-10-07 Chemeq Ltd Topical antimicrobial compositions

Also Published As

Publication number Publication date
CN108472311A (zh) 2018-08-31
EP3416656A4 (en) 2019-11-13
JP2019510731A (ja) 2019-04-18
HK1254547A1 (zh) 2019-07-19
US11045491B2 (en) 2021-06-29
JP6812436B2 (ja) 2021-01-13
WO2017139849A1 (en) 2017-08-24
AU2017220391A1 (en) 2018-05-17
EP3416656A1 (en) 2018-12-26
AU2017220391B2 (en) 2023-01-19
US20210275573A1 (en) 2021-09-09
AU2023201883B2 (en) 2024-08-08
AU2023201883A1 (en) 2023-05-04
US20180338994A1 (en) 2018-11-29
EP3416656B1 (en) 2021-04-21
ES2867453T3 (es) 2021-10-20

Similar Documents

Publication Publication Date Title
AU2023201883B2 (en) Anti-virus agent and method for treatment of viral infection
Yoshimoto et al. Development of Anti‐influenza Drugs: II. Improvement of Oral and Intranasal Absorption and the Anti‐influenza Activity of Stachyflin Derivatives
JP6605602B2 (ja) 細菌感染の治療のためのコポリマーおよび方法
HK1254547B (zh) 抗病毒剂和治疗病毒感染的方法
US20220401469A1 (en) Process for preparation of biologically active copolymer
WO2021236672A2 (en) Compositions and methods for prevention of coronavirus infection
CA3179278A1 (en) Compositions and methods of treatment with glutathione
Jiang et al. Curcumin activates the JAK-STAT signaling pathway to enhance the innate immune response against porcine epidemic diarrhea virus infection in vivo and in vitro
US20240150441A1 (en) Monoclonal antibodies against sars-cov-2 and variants
CN118613256A (zh) 通过酚化合物与羰基化合物的反应得到的作为抗SARS-CoV-2药剂的聚合物
WO2007040426A1 (en) Antiviral agent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1254547

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant